Yingxi Smart rose more than 9% in the morning, the company reached a $2.75 billion partnership with Eli Lilly

InnoSilicon (03696) surged more than 10% in the early trading session. As of the time of publication, the stock price is up 8.93%, currently trading at HK$61, with a trading volume of HK$205 million.

Recently, Eli Lilly and InnoSilicon reached a major collaboration. Eli Lilly received the exclusive sales rights to a GLP-1 diabetes drug developed using AI technology from InnoSilicon. The upfront payment is US$115 million, and the total amount could reach as high as US$2.75 billion. Under the terms of the collaboration, Eli Lilly will obtain the right to use InnoSilicon’s artificial intelligence platform. The two sides will jointly apply the platform’s “AI engine” to accelerate the discovery and development process for new drugs across multiple therapeutic areas

(Editor: He Chong)

     【Disclaimer】This article only represents the author’s personal views and is not related to Hexun. The Hexun website maintains a neutral stance toward the statements and views in the text, and does not provide any explicit or implied guarantees regarding the accuracy, reliability, or completeness of the content. Readers are requested to use this information only as a reference and bear all responsibility for their own actions. Email: news_center@staff.hexun.com

Report